Study of BC3195 for advanced or metastatic cancer
Part of Cancer clinical trials.
This trial tests a new drug called BC3195 in people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective for cancers that express a specific marker called CDH3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced or metastatic solid tumors that have not improved with standard treatments.
- You must agree to provide a tumor tissue sample from a previous biopsy or a new one.
- You must have at least one tumor that can be measured on scans.
- You must have adequate organ function and a life expectancy of at least 3 months.
- You must use effective contraception if you or your partner can have children, for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This trial tests a new drug called BNT317 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if BNT317 is safe and if it can help shrink tumors.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.